Drug Profile
LT 3001
Alternative Names: I-037; LT3001Latest Information Update: 07 Feb 2024
Price :
$50
*
At a glance
- Originator Lumosa Therapeutics
- Developer Lumosa Therapeutics; Shanghai Pharmaceutical Group
- Class Antithrombotics; Neuroprotectants; Peptides; Small molecules; Vascular disorder therapies
- Mechanism of Action Antioxidants; Fibrinolytic agents; Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Stroke